Every article, report, and earnings note where ROIV appears.
Roivant Sciences Ltd. (ROIV) jumps after reporting positive Phase 2 data for mosliciguat in PH-ILD. The readout boosted investor sentiment as the company advanced the program into Phase 3, though the stock now trades above its consensus target and still faces clinical and commercial execution risk.
Roivant Sciences is a cash-rich biotech platform with a near-term brepocitinib launch and several late-stage catalysts, but valuation already reflects meaningful execution risk. The stock is a Hold as investors wait for commercial proof and clinical readouts.
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.
Summit Therapeutics is trading like the financing scare already came and went. The rebound says the market cares more about ivonescimab's November 14, 2026 FDA clock and funded Phase III runway than a headline offering that never even closed.
Roivant Sciences Ltd. (ROIV) climbs after hours following its May 20 earnings and business update. The biotech’s rally is tied to encouraging pipeline progress, strong cash reserves, and analyst optimism, pushing shares above their prior 52-week high as investors reassess the company’s platform value.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ROIV ReportCancel anytime